Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Allergy Partners Myth Busters: Do Allergy Shots Really Work?
  • USA - English


News provided by

Allergy Partners

Jan 02, 2019, 03:00 ET

Share this article

Share toX

Share this article

Share toX


ASHEVILLE, N.C. (PRWEB) January 02, 2019 -- Inspired by one of our favorite television shows, Allergy Myth Busters looks at a number of popularly held beliefs about allergy. But are these myths just urban legends or are they true?

MYTH: Allergy Shots Don’t Work.

The myth that immunotherapy does NOT work is BUSTED! However, like any medical treatment, the success of immunotherapy rests on proper diagnosis, selection of the best therapy, and, importantly, the right dosage.

Post this

THE SCIENCE: Immunotherapy, commonly called allergy shots, was first introduced in 1911. Immunotherapy is a unique way of treating allergies and asthma. Medications treat the symptoms of allergies. Immunotherapy, however, changes the way a person’s immune system is reacting to the environment. In allergic people, the immune system is reacting to common things in the environment such as pollens or pet dander. This leads to classic symptoms of hay fever and, in some, asthma. Allergen skin testing identifies a person’s allergic triggers. A personalized vaccine is then formulated using all natural protein extracts. This extract is then administered to teach the immune system to tolerate exposure to allergens in the environment. And while some claim that immunotherapy is not helpful, a strong body of scientific evidence demonstrates that immunotherapy, when done correctly, leads to:

  • 60-70% reduction in allergy symptoms with a 70% fall in need for medications
  • Improved asthma control while reducing need for medications
  • Reduction of an allergic child’s risk of developing asthma by up to 60%
  • Reduced risk of developing new allergies
  • Improved quality of life
  • Long lasting symptom improvement in 85% of patients that persists after the treatment is stopped

Immunotherapy is generally safe and well tolerated, but like all medical treatment has some risk. Since immunotherapy uses natural extracts of the very things to which a person is allergic, it can cause allergic reactions. Most such reactions are localized but they can be generalized, called anaphylaxis. Again, most of these generalized reactions are mild but in some cases they can be severe and even life threatening. It is therefore very important that immunotherapy be given under the supervision of a Board Certified Allergist.

Immunotherapy can be given by several methods.

Injections: Known as Subcutaneous Immunotherapy or SCIT. This can be administered through a Classic or Cluster protocol in a physician’s office.

Drops: Known as Sublingual Immunotherapy or SLIT. This can be administered at home.

Classic SCIT: In Classic SCIT, patients receive allergy injections in two phases: Build-up and Maintenance.

Build up Phase: Patients initially receive very low doses of allergens by subcutaneous (i.e. into the tissue just under the skin) injection. Patients receive shots once or twice a week. With each shot, the dose is slowly increased to build immune system tolerance. After each shot, the person is monitored for 30 minutes for any reaction. For most patients, the build-up phase is 28 doses.

Maintenance Phase: Once the top, or maintenance, dose is reached, shots are spaced out to every 2-4 weeks. During this time the dose of allergen remains constant. Typically, a person will be on Classic SCIT for 3-5 years.

Cluster Build up – Cluster SCIT is very similar to Classic SCIT except the build-up phase is much quicker. In Cluster, the build-up period is condensed into 9 sessions held once or, ideally, twice a week. At each session, the patient will receive 2-3 doses of immunotherapy separated by 30 minutes waiting periods. This can allow a patient to reach maintenance in as few as 4 weeks. The maintenance phase is the same as in Classic IT.

Advantages:

1. Can reach maintenance is as few as 4 weeks
2. May see quicker results
3. May be more convenient

Disadvantages

1. Sessions can be up to 90 minutes
2. Increased rates of local reactions and premedication with an antihistamine is recommended
3. May not be suited to very sensitive patients

Sublingual Immunotherapy (SLIT)

Unlike Classic and Cluster IT that utilizes shots, SLIT utilized allergens administered in a liquid or tablet form under the tongue to achieve similar changes in the immune system. Similar to SCIT, an extract is prepared based upon a person’s history and skin test results. SLIT has a favorable side effect profile. Common side effects are local itching/burning of the mouth or lips or GI upset. More serious side effects are very rare. Therefore, the first dose of SLIT is administered in a doctor’s office but then is taken at home on a daily basis.

Advantages:

1. Fewer allergic reactions
2. No need for injections
3. Can be administered at home
4. May be better suited for patients who have only seasonal allergy symptoms

Disadvantages:

1. May not be as effective as SCIT
2. May not be as effective for patients with multiple allergens
3. Out of pocket costs may be increased
4. Unclear if SLIT has the same preventative capabilities of SCIT

Choosing whether immunotherapy and which type of immunotherapy is right for you is a critical part of your health care. Your Allergy Partners physician will work with you to discern what will work best for you.

THE VERDICT: The myth that immunotherapy does NOT work is BUSTED! However, like any medical treatment, the success of immunotherapy rests on proper diagnosis, selection of the best therapy, and, importantly, the right dosage. If these key elements are lacking, immunotherapy may not give the expected results, leading to the myth that immunotherapy does not work. All Allergy Partners physicians are Board Certified Allergist Immunologists with years of experience treating asthma, allergies, sinusitis and other allergic diseases. Our immunotherapy program is the nation’s largest and utilizes optimized dosages that improve how well immunotherapy works (efficacy) and minimize side effects. We offer the full range of immunotherapy options as noted above. Immunotherapy is customized for each person, because safety and efficacy are paramount. Allergy Partners continuously collects safety data and reviews immunotherapy dosing recommendations to ensure that our patients receive the highest quality immunotherapy possible.

To learn more about immunotherapy and how it may benefit you, visit Allergypartners.com

Contact Information: 

Amanda Reed, Marketing and Corporate Communications Manager 
Allergy Partners, P.A. 
Phone: 828-277-1300 
Fax: 828-277-2499
[email protected] 
https://www.allergypartners.com/ 
PR: NOVA Advertising

Amanda Reed, Allergy Partners, http://www.allergypartners.com, 828-277-1300, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.